SEC Filing - bluebird bio, Inc.
Articles with bluebird bio
Bluebird Bio (BLUE) FDA Panel Ruling on Gene Therapy Drug May Help Stock - Bloomberg
bluebird bio's (BLUE) 52 Week High at $8.49 & Low at $2.94
Here's How bluebird bio, Inc. Crushed It in 2017
bluebird bio | Pioneering Gene Therapies | Recode for Life
bluebird bio's (BLUE) COGS at $5.396 Million
bluebird bio, Inc. - AnnualReports.com
Bluebird Bio Says Cash Crunch Raises 'Going Concern' Risk - Bloomberg
bluebird bio, Inc. signs new 61,000 s/f lease at Assembly Row : NEREJ
bluebird bio: One Of My Top Picks For 2021 (NASDAQ:BLUE) | Seeking Alpha
bluebird bio, Inc. (BLUE) Company Profile & Overview - Stock Analysis
bluebird bio (@bluebirdbio) / Twitter
BlackRock Inc. Increases Position in bluebird bio Inc (BLUE) | Nasdaq
Why Bluebird Bio (BLUE) Stock Is Getting Hammered | Markets Insider
bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock
BS/MS level Position at Bluebird Bio to work on CAR-T cells
bluebird bio reveals plans to launch two gene therapies - PMLiVE
bluebird bio (@bluebirdbio) / Twitter
blue-ex991_6.htm
bluebird bio - YouTube
Bluebird Bio: Stock Price Climbing on FDA Gene Therapy Approval - TipRanks.com
